Compare Stocks: DCPH, BLTE, LNTH, and AMRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$20.50 +3.7%	$18.13	$9.56 ▼ $21.17	$6.31B	1.24	2.51 million shs	2.78 million shs
BLTE Belite Bio	$165.93 -0.8%	$165.86	$70.17 ▼ $200.00	$6.74B	-1.23	204,273 shs	114,228 shs
DCPH Deciphera Pharmaceuticals	$25.59	$25.59	$9.90 ▼ $25.61	$2.21B	0.19	1.29 million shs	N/A
LNTH Lantheus	$99.74	$101.16	$49.67 ▼ $111.86	$6.51B	-0.03	918,209 shs	1.20 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	0.00%	+5.67%	+12.71%	+14.34%	+102.77%
BLTE Belite Bio	0.00%	-2.12%	+10.29%	+8.20%	+139.11%
DCPH Deciphera Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
LNTH Lantheus	0.00%	-0.81%	-1.02%	-8.98%	+97.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$20.50 +3.7%	$18.13	$9.56 ▼ $21.17	$6.31B	1.24	2.51 million shs	2.78 million shs
BLTE Belite Bio	$165.93 -0.8%	$165.86	$70.17 ▼ $200.00	$6.74B	-1.23	204,273 shs	114,228 shs
DCPH Deciphera Pharmaceuticals	$25.59	$25.59	$9.90 ▼ $25.61	$2.21B	0.19	1.29 million shs	N/A
LNTH Lantheus	$99.74	$101.16	$49.67 ▼ $111.86	$6.51B	-0.03	918,209 shs	1.20 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	0.00%	+5.67%	+12.71%	+14.34%	+102.77%
BLTE Belite Bio	0.00%	-2.12%	+10.29%	+8.20%	+139.11%
DCPH Deciphera Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
LNTH Lantheus	0.00%	-0.81%	-1.02%	-8.98%	+97.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRX Amneal Pharmaceuticals	2.90	Moderate Buy	$21.00	2.44% Upside
BLTE Belite Bio	2.64	Moderate Buy	$218.73	31.82% Upside
DCPH Deciphera Pharmaceuticals	0.00	N/A	N/A	N/A
LNTH Lantheus	2.29	Hold	$108.11	8.39% Upside

Current Analyst Ratings Breakdown

Latest DCPH, BLTE, LNTH, and AMRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
9/23/2026	AMRX Amneal Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$27.00
9/17/2026	AMRX Amneal Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$16.00 ➝ $20.00
9/10/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
9/9/2026	BLTE Belite Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$220.00 ➝ $234.00
9/9/2026	BLTE Belite Bio	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
9/9/2026	AMRX Amneal Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$23.00
9/9/2026	AMRX Amneal Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$23.00
9/8/2026	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$245.00
9/7/2026	AMRX Amneal Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/4/2026	BLTE Belite Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$303.00

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRX Amneal Pharmaceuticals	$3.02B	2.17	$1.62 per share	12.66	($0.23) per share	-89.13
BLTE Belite Bio	N/A	N/A	N/A	N/A	$20.54 per share	N/A
DCPH Deciphera Pharmaceuticals	$174.91M	12.65	N/A	N/A	$4.38 per share	5.84
LNTH Lantheus	$1.54B	4.22	$6.39 per share	15.62	$16.43 per share	6.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRX Amneal Pharmaceuticals	$72.06M	$0.49	41.84	18.98	2.32	5.05%	-584.46%	7.78%	N/A
BLTE Belite Bio	-$77.61M	-$2.73	N/A	182.34	N/A	N/A	-11.84%	-11.62%	11/9/2026 (Estimated)
DCPH Deciphera Pharmaceuticals	-$194.94M	-$2.21	N/A	N/A	N/A	-108.86%	-52.42%	-40.05%	N/A
LNTH Lantheus	$233.56M	$4.14	24.09	18.27	N/A	17.69%	28.10%	14.35%	11/5/2026 (Estimated)

Latest DCPH, BLTE, LNTH, and AMRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	BLTE Belite Bio	-$0.73	-$0.54	+$0.19	-$0.70	N/A	N/A
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
7/30/2026	Q2 2026	AMRX Amneal Pharmaceuticals	$0.24	$0.30	+$0.06	$0.18	N/A	$796.20 million
6/30/2026	Q2 2026	BLTE Belite Bio	N/A	-$0.54	N/A	-$0.70	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRX Amneal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
DCPH Deciphera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRX Amneal Pharmaceuticals	77.65	2.20	1.44
BLTE Belite Bio	N/A	33.56	33.56
DCPH Deciphera Pharmaceuticals	N/A	4.19	3.94
LNTH Lantheus	0.43	3.06	2.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRX Amneal Pharmaceuticals	31.82%
BLTE Belite Bio	0.53%
DCPH Deciphera Pharmaceuticals	70.96%
LNTH Lantheus	99.06%

Insider Ownership

Company	Insider Ownership
AMRX Amneal Pharmaceuticals	17.30%
BLTE Belite Bio	13.29%
DCPH Deciphera Pharmaceuticals	4.67%
LNTH Lantheus	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRX Amneal Pharmaceuticals	8,500	319.35 million	264.11 million	Optionable
BLTE Belite Bio	41	40.27 million	34.92 million	Not Optionable
DCPH Deciphera Pharmaceuticals	300	86.48 million	82.44 million	No Data
LNTH Lantheus	1,193	65.27 million	64.16 million	Optionable

DCPH, BLTE, LNTH, and AMRX Headlines

Recent News About These Companies

Lantheus Holdings, Inc. Announces First Patient Dosed In SPARROW Phase 2/3 Registrational Trial Evaluating LNTH-2401 In Prostate Cancer

September 28 at 4:20 PM | marketscreener.comM

Lantheus Holdings, Inc.: Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer

September 28 at 11:19 AM | finanznachrichten.de

Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer

September 28 at 8:00 AM | globenewswire.com

Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval

September 26 at 2:53 PM | finance.yahoo.com

Lantheus Holdings (LNTH) Stock May Be 14% Undervalued On FDA Approval

September 25 at 12:21 AM | finance.yahoo.com

Lantheus (NASDAQ:LNTH) Stock Price Crosses Below 50-Day Moving Average - Here's Why

September 25 at 3:41 AM | americanbankingnews.com

Lantheus (NASDAQ:LNTH) Stock Price Breaks Below Fifty Day Moving Average - Here's What Happened

September 25 at 3:39 AM | marketbeat.com

FDA approval for Lantheus’ Bravnetsa

September 24, 2026 | thepharmaletter.comT

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX)

September 24, 2026 | globenewswire.com

3 Reasons LNTH is Risky and 1 Stock to Buy Instead

September 23, 2026 | finance.yahoo.com

Lantheus Holdings, Inc. Receives Final FDA Approval for BRAVNETSA for Treatment of GEP-NETs

September 22, 2026 | marketscreener.comM

FDA approves Lantheus' Bravnetsa as equivalent to Lutathera for GEP-NETs

September 22, 2026 | streetinsider.com

Lantheus Holdings stock faces a new Curium review window

September 22, 2026 | ad-hoc-news.deA

FDA Approves Lantheus' Bravnetsa As Equivalent To Lutathera For Neuroendocrine Tumors

September 22, 2026 | rttnews.com

Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically ...

September 22, 2026 | finance.yahoo.com

Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs

September 22, 2026 | globenewswire.com

Lantheus Says Curium Resubmits Antitrust Filing for Merger

September 22, 2026 | marketscreener.comM

Lantheus Merger Advances with Renewed Antitrust Review

September 21, 2026 | tipranks.com

California State Teachers Retirement System Sells 2,182 Shares of Lantheus Holdings, Inc. $LNTH

September 13, 2026 | marketbeat.com

Hsbc Holdings PLC Invests $2.27 Million in Lantheus Holdings, Inc. $LNTH

September 12, 2026 | marketbeat.com

Are LNTH, ITGR, CZR Obtaining Fair Deals for their Shareholders?

September 11, 2026 | aol.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCPH, BLTE, LNTH, and AMRX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

$20.50 +0.73 (+3.69%)

Closing price 04:00 PM Eastern

Extended Trading

$20.65 +0.15 (+0.73%)

As of 07:59 PM Eastern

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Belite Bio NASDAQ:BLTE

$165.93 -1.40 (-0.84%)

Closing price 04:00 PM Eastern

Extended Trading

$169.12 +3.19 (+1.92%)

As of 07:30 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Deciphera Pharmaceuticals NASDAQ:DCPH

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Lantheus NASDAQ:LNTH

$99.74 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$99.74 0.00 (0.00%)

As of 07:30 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DCPH, BLTE, LNTH, and AMRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DCPH, BLTE, LNTH, and AMRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DCPH, BLTE, LNTH, and AMRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCPH, BLTE, LNTH, and AMRX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Belite Bio NASDAQ:BLTE

Deciphera Pharmaceuticals NASDAQ:DCPH

Lantheus NASDAQ:LNTH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DCPH, BLTE, LNTH, and AMRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DCPH, BLTE, LNTH, and AMRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DCPH, BLTE, LNTH, and AMRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCPH, BLTE, LNTH, and AMRX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Belite Bio NASDAQ:BLTE

Deciphera Pharmaceuticals NASDAQ:DCPH

Lantheus NASDAQ:LNTH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools